US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLIMB BIO INC

1.27

-0.0300-2.31%

Post-market: 1.270.00000.00%19:58 EDT

Volume:241.65K

Turnover:303.00K

Market Cap:85.69M

PE:-0.83

High:1.37

Open:1.30

Low:1.23

Close:1.30

Loading ...

Overview Company News Filings

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

THOMSON REUTERS

Press Release: Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report

BRIEF-Climb Bio Files For Offering Of Common Stock Up To $22.4 Million - SEC Filing

Climb Bio Inc: Files for Offering of Common Stock up to $22.4 Mln - SEC Filing

THOMSON REUTERS

Climb Bio Reports Fourth Quarter And Year-End 2024 Financial Results And Provides Business Updates

Climb Bio Q4 2024 GAAP EPS $(0.13) Beats $(0.15) Estimate

Climb Bio Inc - Expects Cash Runway Through 2027

THOMSON REUTERS

Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio Appoints Perrin Wilson, Ph.d., as Chief Business Officer

THOMSON REUTERS

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Leerink Partners Sticks to Its Buy Rating for Climb Bio (CLYM)

BUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks

BRIEF-Climb Bio Signs Technology Transfer And License Agreement With Mabworks

Climb Bio Inc - Enters Technology Transfer and License Agreement With Mabworks

THOMSON REUTERS

Climb Bio Inc - to Pay Mabworks up to $832 Million in Milestones

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CLYM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLYM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":1.27,"timestamp":1745611200000,"preClose":1.3,"halted":0,"volume":241645,"hourTrading":{"tag":"盘后","latestPrice":1.27,"preClose":1.27,"latestTime":"19:58 EDT","volume":996,"amount":1265.27,"timestamp":1745625499287},"delay":0,"floatShares":30642992,"shares":67475395,"eps":-1.5343,"marketStatus":"Market Closed","change":-0.03,"latestTime":"04-25 16:00:00 EDT","open":1.3,"high":1.37,"low":1.23,"amount":303001.56523999997,"amplitude":0.107692,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.5343,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":1.3,"postHourTrading":{"tag":"盘后","latestPrice":1.27,"preClose":1.27,"latestTime":"19:58 EDT","volume":996,"amount":1265.27,"timestamp":1745625499287},"volumeRatio":3.0233098709316124},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","floatShares":30642992,"roa":"-10.30%","roe":"-46.26%","lyrEps":-1.5343,"volumeRatio":3.0233098709316124,"shares":67475395,"dividePrice":0,"high":1.37,"amplitude":0.107692,"preClose":1.3,"low":1.23,"week52Low":1.05,"pbRate":"0.40","week52High":11.55,"institutionHeld":0,"latestPrice":1.27,"eps":-1.5343,"divideRate":0,"volume":241645,"delay":0,"ttmEps":-1.5343,"open":1.3,"prevYearClose":1.8,"prevWeekClose":1.26,"prevMonthClose":1.22,"prevQuarterClose":1.22,"fiveDayClose":1.26,"twentyDayClose":1.27,"sixtyDayClose":1.93},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLYM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526598514","title":"Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX","url":"https://stock-news.laohu8.com/highlight/detail?id=2526598514","media":"Exec Edge","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526598514?lang=en_us&edition=fundamental","pubTime":"2025-04-11 01:08","pubTimestamp":1744304892,"startTime":"0","endTime":"0","summary":"Exec Edge today announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates.Exec Edge Research is a highly specialized platform focused on US and global equities, with an emphasis on fundamental analysis. Our first round of initiation reports includes Fold Holdings, Inc , Climb Bio Inc. , Rex American Resources Corp.  and The ONE Group Hospitality, Inc. .It’s time investors consider harvesting a new generation of profits from the vast American Corn Belt with Rex American Resources Corp. . The leading ethanol manufacturer with a stronghold in the U.S. Midwest may soon reap the benefits of two major investment initiatives. With a fully cash-funded investment budget of $165- $175 million, a fraction of cash on hand, a deliberate growth strategy is combined with financial prudence. With a conservative balance sheet, new growth efforts in motion and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exec-edge-launches-research-coverage-170812519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","USJW.SI","PSQ","NVIW.SI","SQQQ","FLDDW","QLD","BK4139","BTC","STKS",".IXIC","CLYM","MNQmain","REX","BK4138","USAW.SI","TQQQ","TSYW.SI","BK4112","FLD","QID","BK4209"],"gpt_icon":1},{"id":"2524191062","title":"Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2524191062","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524191062?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUA7FW8VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","LENZ","ABOS","IMU.AU","BK4139","BK7067","VERV","BK4539","SLDB","CLYM"],"gpt_icon":0},{"id":"2524191799","title":"Press Release: Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2524191799","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524191799?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors. WELLESLEY HILLS, Mass., April 01, 2025  -- Climb Bio, Inc.  today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair.Bo Cumbo brings over 30 years of experience in the pharmaceutical and biotechnology industries, with a proven track record of leading successful commercial launches for 11 specialty and rare disease therapies. He currently serves as President, Chief Executive Officer, and director of Solid Biosciences . Previously, Mr. Cumbo was President and Chief Executive Officer of AavantiBio, Inc. Before that, he held key leadership roles at Sarepta Therapeutics, Inc., where he most recently served as Executive Vice President and Chief Commercial Officer. Earlier in his career, he held","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","BK4139","CLYM"],"gpt_icon":0},{"id":"2522637936","title":"Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2522637936","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522637936?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"WELLESLEY, Mass., March 27, 2025  -- Climb Bio, Inc.  today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.24th Annual Needham Virtual Healthcare Conference Format: Presentation and one-on-one investor meetingsDate: April 10, 2025Time: 8:45 a.m. ETWebcast:Click here. About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/climb-bio-present-24th-annual-110000919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","BK4139","CLYM","HCSG"],"gpt_icon":0},{"id":"2522359149","title":"Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2522359149","media":"Exec Edge","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522359149?lang=en_us&edition=fundamental","pubTime":"2025-03-27 04:38","pubTimestamp":1743021535,"startTime":"0","endTime":"0","summary":"Climb Bio, Inc.  reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.As we highlighted in our 66-page initiation report last week , CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy , systemic lupus erythematosus and lupus nephritis , and immune thrombocytopenia . The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4199","CLYM","ITP"],"gpt_icon":0},{"id":"2522382688","title":"BRIEF-Climb Bio Files For Offering Of Common Stock Up To $22.4 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522382688","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522382688?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:40","pubTimestamp":1742935215,"startTime":"0","endTime":"0","summary":"BRIEF-Climb Bio Files For Offering Of Common Stock Up To $22.4 Million - SEC FilingMarch 25  - Climb Bio Inc CLYM.O:CLIMB BIO INC: FILES FOR OFFERING OF COMMON STOCK UP TO $22.4 MILLION - SEC FILINGSource text: [ID:n0001193125-25-062602]Further company coverage: CLYM.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2522838155","title":"Climb Bio Inc: Files for Offering of Common Stock up to $22.4 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522838155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522838155?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:39","pubTimestamp":1742935160,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLYM"],"gpt_icon":0},{"id":"2522634880","title":"Climb Bio Reports Fourth Quarter And Year-End 2024 Financial Results And Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522634880","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522634880?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:20","pubTimestamp":1742934019,"startTime":"0","endTime":"0","summary":"March 25 (Reuters) - Climb Bio Inc ::*CLIMB BIO REPORTS FOURTH QUARTER AND YEAR-END 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES*CLIMB BIO INC - EXPECTS CASH RUNWAY THROUGH 2027*CLIMB BIO INC:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nRSDrXHnL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM"],"gpt_icon":0},{"id":"2522288770","title":"Climb Bio Q4 2024 GAAP EPS $(0.13) Beats $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522288770","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522288770?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:08","pubTimestamp":1742933328,"startTime":"0","endTime":"0","summary":"Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is unchanged from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44481370/climb-bio-q4-2024-gaap-eps-0-13-beats-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM"],"gpt_icon":0},{"id":"2522871948","title":"Climb Bio Inc - Expects Cash Runway Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2522871948","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522871948?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:05","pubTimestamp":1742933108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA76YNVP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2522887962","title":"Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522887962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522887962?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:05","pubTimestamp":1742933100,"startTime":"0","endTime":"0","summary":"Received Clearance from the U.S. Food and Drug Administration  for Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus . Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position. Expanded Pipeline to Include CLYM116, an Anti-APRIL  Monoclonal Antibody for Treatment of IgA Nephropathy . Appointed Perrin Wilson, Ph.D. as Chief Business Officer. Ended 2024 in a Strong Financial Position, with Cash Runway Expected Through 2027. received clearance from the FDA to initiate a Phase 2 clinical trial of. budoprutug in patients with pMN. This open-label, dose-ranging","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","SLE","BK4199","CLYM","BK4139","BK4077"],"gpt_icon":0},{"id":"2521498530","title":"Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2521498530","media":"Exec Edge","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521498530?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:07","pubTimestamp":1742494024,"startTime":"0","endTime":"0","summary":"As one of the brightest emerging biotechnology companies, Climb Bio Inc.  aims to improve the efficacy of autoimmune disease treatment. With its recently acquired lead asset, Budoprutug, and exclusively licensed Anti-APRIL antibody, CLYM116, the innovative biotech play is positioned to pull ahead of the pack. We expect 2025 to be a momentous year for the newcomer, based on a best-in-class treatment pipeline.Autoimmune diseases affect about 7.6-9.4% of the population globally. Within this market, CLYM has identified four focus areas that build the foundation of its strategy. Our report focuses heavily on the technicalities of the due diligence process, the scientific background of Budoprutug and CLYM116, and how it offers effective treatment for B Cell-mediated conditions and IgA Nephropathy.For equity investors awaiting signs of success in Climb Bio’s drug development and trials, the company offers long-term security through a strong balance sheet, including cash reserves of $212 milli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/climb-bio-meet-newest-star-180704750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CLYM"],"gpt_icon":0},{"id":"2514095261","title":"Climb Bio to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514095261","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514095261?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":"WELLESLEY, Mass., Feb. 25, 2025  -- Climb Bio, Inc.  today announced that members of its executive team will participate in the upcoming investor conferences detailed below.TD Cowen 45th Annual Health Care Conference Format: Formal presentation and one-on-one investor meetingsDate: March 4, 2025Time: 9:50 a.m. ETWebcast:Click here. Leerink’s Global Healthcare Conference 2025Format: Fireside chat and one-on-one investor meetings Date: March 10, 2025Time: 10:00 a.m. ETWebcast: Click here. About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/climb-bio-present-upcoming-investor-120000462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CLYM"],"gpt_icon":0},{"id":"2513740638","title":"Climb Bio Appoints Perrin Wilson, Ph.d., as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2513740638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513740638?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:00","pubTimestamp":1740398402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA37L8H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2513629740","title":"Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2513629740","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513629740?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:00","pubTimestamp":1740398400,"startTime":"0","endTime":"0","summary":"WELLESLEY HILLS, Mass., Feb. 24, 2025  -- Climb Bio, Inc.  announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry.About Climb Bio, Inc.Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/climb-bio-appoints-perrin-wilson-120000226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CLYM"],"gpt_icon":0},{"id":"2503340460","title":"Leerink Partners Sticks to Its Buy Rating for Climb Bio (CLYM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503340460","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503340460?lang=en_us&edition=fundamental","pubTime":"2025-01-13 13:56","pubTimestamp":1736747779,"startTime":"0","endTime":"0","summary":"In a report released on January 9, Thomas Smith from Leerink Partners reiterated a Buy rating on Climb Bio (CLYM – Research Report). The company’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-climb-bio-clym?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-climb-bio-clym?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM"],"gpt_icon":0},{"id":"2502860910","title":"BUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks","url":"https://stock-news.laohu8.com/highlight/detail?id=2502860910","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502860910?lang=en_us&edition=fundamental","pubTime":"2025-01-10 23:08","pubTimestamp":1736521733,"startTime":"0","endTime":"0","summary":"BUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks** Biotech firm Climb Bio's CLYM.O shares rise ~16% to $2.17** CLYM announces license deal with Beijing Mabworks Biotech Co Ltd in a filing** CLYM buys exclusive right to develop, manufacture, and commercialize Mabworks' MIL116 antibody outside of China, Hong Kong, Macau, and Taiwan, with non-exclusive rights for global clinical studies in those regions** MIL116, now called CLYM116, is an antibody developed by Mabworks for treating autoimmune diseases, including IgA nephropathy and B-cell mediated diseases** Autoimmune diseases occur when the immune system attacks the body's own tissues** CLYM will pay Mabworks $9 mln upfront and up to $832 mln upon reaching certain commercial milestones** Mabworks has the first right to develop and sell the antibody in China - filing** CLYM fell 35.7% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nL4N3O610J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM"],"gpt_icon":0},{"id":"2502869825","title":"BRIEF-Climb Bio Signs Technology Transfer And License Agreement With Mabworks","url":"https://stock-news.laohu8.com/highlight/detail?id=2502869825","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502869825?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:53","pubTimestamp":1736517197,"startTime":"0","endTime":"0","summary":"Jan 10 (Reuters) - Climb Bio Inc   :   * CLIMB BIO INC - ENTERS TECHNOLOGY TRANSFER AND LICENSE AGREEMENT WITH MABWORKS   * CLIMB BIO INC - TO PAY MABWORKS UP TO $832 MILLION IN MILESTONESSource text:  Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM"],"gpt_icon":0},{"id":"2502863656","title":"Climb Bio Inc - Enters Technology Transfer and License Agreement With Mabworks","url":"https://stock-news.laohu8.com/highlight/detail?id=2502863656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502863656?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:10","pubTimestamp":1736514618,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nFWN3O60IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2502659863","title":"Climb Bio Inc - to Pay Mabworks up to $832 Million in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2502659863","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502659863?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:10","pubTimestamp":1736514618,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nFWN3O60IF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLYM"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLYM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-09-13","symbol":"CLYM","fiscalQuarterEnding":"2021/06","expectedEps":-2.3,"name":null,"time":"","type":"earning","dateTimestamp":1631505600000,"reportTimeType":"","actualEps":-3.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLYM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLYM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1733198400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLYM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLYM","date":"2025-04-24","current":-1.223555,"percent":0.852941,"low":-5.682799,"twenty":-3.619939,"median":-1.876998,"eighty":-1.297365,"high":-1.031804,"avg":-2.428947,"sd":1.343581,"marketCap":90417029},"quantilePoints":[{"date":"2024-10-04","current":-5.327624,"twenty":-5.327624,"median":-5.327624,"eighty":-5.327624,"marketCap":342006831},{"date":"2024-10-11","current":-5.369409,"twenty":-5.463426,"median":-5.390302,"eighty":-5.369409,"marketCap":344689237},{"date":"2024-10-18","current":-5.076912,"twenty":-5.494765,"median":-5.390302,"eighty":-5.327624,"marketCap":325912392},{"date":"2024-10-25","current":-4.85754,"twenty":-5.463426,"median":-5.327624,"eighty":-5.014234,"marketCap":311829757},{"date":"2024-10-31","current":-4.094958,"twenty":-5.404927,"median":-5.238831,"eighty":-4.776059,"marketCap":262875838},{"date":"2024-11-08","current":-3.677105,"twenty":-5.390302,"median":-5.014234,"eighty":-4.074065,"marketCap":236051773},{"date":"2024-11-15","current":-3.107258,"twenty":-5.373588,"median":-4.888879,"eighty":-3.806639,"marketCap":214779913},{"date":"2024-11-22","current":-2.917613,"twenty":-5.335981,"median":-4.293438,"eighty":-3.619939,"marketCap":201671280},{"date":"2024-11-29","current":-3.141297,"twenty":-5.327624,"median":-4.220314,"eighty":-3.127681,"marketCap":217132744},{"date":"2024-12-06","current":-2.830085,"twenty":-5.277482,"median":-3.974826,"eighty":-3.040153,"marketCap":195621141},{"date":"2024-12-13","current":-2.742557,"twenty":-5.237786,"median":-3.781569,"eighty":-2.995417,"marketCap":189571003},{"date":"2024-12-20","current":-1.896449,"twenty":-5.13959,"median":-3.671882,"eighty":-2.96235,"marketCap":131086332},{"date":"2024-12-27","current":-2.207661,"twenty":-5.051841,"median":-3.301766,"eighty":-2.921503,"marketCap":152597935},{"date":"2025-01-03","current":-2.013153,"twenty":-5.003788,"median":-3.151022,"eighty":-2.57139,"marketCap":139153183},{"date":"2025-01-10","current":-1.818646,"twenty":-4.962003,"median":-3.124277,"eighty":-2.236837,"marketCap":125708431},{"date":"2025-01-17","current":-1.954801,"twenty":-4.920218,"median":-3.063494,"eighty":-2.032604,"marketCap":135119757},{"date":"2025-01-24","current":-1.770019,"twenty":-4.870076,"median":-3.005142,"eighty":-1.952856,"marketCap":122347243},{"date":"2025-01-31","current":-1.876998,"twenty":-4.531614,"median":-2.995417,"eighty":-1.91979,"marketCap":129741856},{"date":"2025-02-07","current":-1.701941,"twenty":-4.324777,"median":-2.96624,"eighty":-1.892559,"marketCap":117641580},{"date":"2025-02-14","current":-1.546335,"twenty":-4.251653,"median":-2.932201,"eighty":-1.865328,"marketCap":106885778},{"date":"2025-02-21","current":-1.400454,"twenty":-4.228671,"median":-2.873849,"eighty":-1.840042,"marketCap":96802214},{"date":"2025-02-28","current":-1.351828,"twenty":-4.1451,"median":-2.528598,"eighty":-1.818646,"marketCap":93441026},{"date":"2025-03-07","current":-1.429631,"twenty":-4.03228,"median":-2.256288,"eighty":-1.756403,"marketCap":98818927},{"date":"2025-03-14","current":-1.293475,"twenty":-3.971692,"median":-2.18821,"eighty":-1.542445,"marketCap":89407600},{"date":"2025-03-21","current":-1.244848,"twenty":-3.871407,"median":-2.022879,"eighty":-1.474368,"marketCap":86046412},{"date":"2025-03-28","current":-1.159638,"twenty":-3.794104,"median":-1.954801,"eighty":-1.429631,"marketCap":85693751},{"date":"2025-04-04","current":-1.050066,"twenty":-3.724618,"median":-1.940213,"eighty":-1.381004,"marketCap":77596704},{"date":"2025-04-11","current":-1.059197,"twenty":-3.680923,"median":-1.925625,"eighty":-1.357663,"marketCap":78271458},{"date":"2025-04-17","current":-1.150507,"twenty":-3.672927,"median":-1.896449,"eighty":-1.324596,"marketCap":85018997},{"date":"2025-04-24","current":-1.223555,"twenty":-3.619939,"median":-1.876998,"eighty":-1.297365,"marketCap":90417029}],"updateTime":1745635102825}}}